BRIEF-Novabay Pharmaceuticals' Auriclosene demonstrates significant results in Phase 2B
September 19, 2016 at 07:09 AM EDT
* Novabay Pharmaceuticals' Auriclosene demonstrates statistically significant and clinically meaningful results in Phase 2B study for the prevention of urinary catheter blockage and encrustation
